CoMind has raised $102,500,000 from investors to accelerate its mission in revolutionising brain healthcare with its non-invasive technology. The London-based company has secured this significant investment to advance its groundbreaking approach to redefining how the brain is measured and treated, aiming to optimise patient outcomes across the care continuum.
The company designs and manufactures innovative brain monitoring solutions that provide a multidimensional view of brain activity using light. Its AI-powered platform, CoVision, delivers predictive insights, enabling clinicians to anticipate complications. This technology is designed to enhance patient safety, improve healthcare economics, and improve clinical outcomes across various critical settings, from intensive care units to operating theatres and emergency rooms. CoMind focuses on precision medicine, setting new standards in brain health.
This substantial capital infusion underscores investor confidence in CoMind's innovative technology and its potential to transform neurological care. CoMind plans to strategically deploy the funds for a range of growth initiatives, including accelerating ongoing research and development efforts, scaling manufacturing capabilities to meet anticipated demand, and expanding its market reach into new territories. The company is backed by a syndicate of leading investors such as Octopus Ventures, LocalGlobe, Angelini Ventures, and Crane Venture Partners, alongside several high-profile angel investors.
The newly raised capital is expected to significantly bolster CoMind's capabilities, allowing it to further develop its non-invasive brain monitoring solutions and strengthen its global presence. This investment reinforces CoMind’s position at the forefront of neurological innovation, supporting its long-term vision for improved patient care worldwide.
